VNRX vs. TNGX, MNPR, MDWD, ALMS, INMB, TVGN, INBX, CKPT, FDMT, and NMRA
Should you be buying VolitionRx stock or one of its competitors? The main competitors of VolitionRx include Tango Therapeutics (TNGX), Monopar Therapeutics (MNPR), MediWound (MDWD), Alumis (ALMS), INmune Bio (INMB), Tevogen Bio (TVGN), Inhibrx (INBX), Checkpoint Therapeutics (CKPT), 4D Molecular Therapeutics (FDMT), and Neumora Therapeutics (NMRA). These companies are all part of the "pharmaceutical products" industry.
VolitionRx vs.
VolitionRx (NYSE:VNRX) and Tango Therapeutics (NASDAQ:TNGX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends, valuation and community ranking.
VolitionRx has higher earnings, but lower revenue than Tango Therapeutics. VolitionRx is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, VolitionRx had 2 more articles in the media than Tango Therapeutics. MarketBeat recorded 6 mentions for VolitionRx and 4 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.48 beat VolitionRx's score of 0.20 indicating that Tango Therapeutics is being referred to more favorably in the news media.
Tango Therapeutics received 17 more outperform votes than VolitionRx when rated by MarketBeat users. Likewise, 73.68% of users gave Tango Therapeutics an outperform vote while only 18.03% of users gave VolitionRx an outperform vote.
VolitionRx has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.
VolitionRx presently has a consensus price target of $3.75, indicating a potential upside of 569.64%. Tango Therapeutics has a consensus price target of $12.33, indicating a potential upside of 658.97%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than VolitionRx.
8.1% of VolitionRx shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 12.8% of VolitionRx shares are held by insiders. Comparatively, 6.3% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Tango Therapeutics has a net margin of -284.42% compared to VolitionRx's net margin of -2,321.14%. VolitionRx's return on equity of 0.00% beat Tango Therapeutics' return on equity.
Summary
Tango Therapeutics beats VolitionRx on 11 of the 18 factors compared between the two stocks.
Get VolitionRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VolitionRx Competitors List
Related Companies and Tools
This page (NYSE:VNRX) was last updated on 3/26/2025 by MarketBeat.com Staff
Buy VNRX Stock Free VNRX Stock Alerts